533,784 Shares in Stryker Corporation $SYK Purchased by Veritas Asset Management LLP

Key Points

• Veritas Asset Management acquired 533,784 Stryker shares worth approximately $168.1 million, making the position 3.1% of its portfolio and about 0.14% of Stryker’s outstanding stock.
• Stryker shares fell 8.9% to $276.16, near the company’s 52-week low, despite quarterly results that exceeded analysts’ EPS and revenue estimates. The company reported 9.4% year-over-year revenue growth and maintained 2026 EPS guidance of $14.95–$15.10.
• Director Ronda E. Stryker and other insiders sold approximately $118.2 million of stock over the past 90 days, while the company declared a quarterly dividend of $0.88 per share, yielding about 1.3% annually.

Veritas Asset Management LLP bought a new stake in Stryker Corporation (NYSE:SYK - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 533,784 shares of the medical technology company's stock, valued at approximately $168,057,000. Stryker comprises approximately 3.1% of Veritas Asset Management LLP's holdings, making the stock its 14th biggest holding. Veritas Asset Management LLP owned about 0.14% of Stryker at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Gables Capital Management Inc. acquired a new position in shares of Stryker in the 2nd quarter worth approximately $25,000. Kilter Group LLC acquired a new stake in Stryker in the 2nd quarter valued at approximately $25,000. Highland Investment Advisors LLC purchased a new stake in Stryker in the second quarter valued at approximately $25,000. Cornerstone Financial Management LLC lifted its stake in Stryker by 66.0% during the second quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company's stock worth $25,000 after purchasing an additional 31 shares in the last quarter. Finally, Godfrey Financial Associates Inc. purchased a new position in shares of Stryker during the fourth quarter worth $26,000. Hedge funds and other institutional investors own 77.09% of the company's stock.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 300,000 shares of the company's stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the sale, the director directly owned 2,301,375 shares of the company's stock, valued at $773,031,862.50. This represents a 11.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Debra King sold 826 shares of Stryker stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the transaction, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 351,267 shares of company stock worth $118,197,701 over the last 90 days. Corporate insiders own 4.60% of the company's stock.

Stryker Stock Down 8.9%

Shares of SYK traded down $26.97 during midday trading on Tuesday, reaching $276.16. The stock had a trading volume of 6,316,453 shares, compared to its average volume of 2,382,455. The company has a market cap of $105.93 billion, a price-to-earnings ratio of 28.62, a PEG ratio of 1.90 and a beta of 0.76. The company's fifty day simple moving average is $327.52 and its two-hundred day simple moving average is $328.30. Stryker Corporation has a 1-year low of $275.10 and a 1-year high of $395.90. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to analysts' expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business's quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts expect that Stryker Corporation will post 15.03 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.3%. Stryker's payout ratio is 36.48%.

Analyst Ratings Changes

Several equities research analysts recently issued reports on SYK shares. Citizens Jmp cut their price objective on Stryker from $440.00 to $400.00 and set a "market outperform" rating on the stock in a report on Monday, August 3rd. BMO Capital Markets initiated coverage on shares of Stryker in a research note on Wednesday, July 8th. They set an "outperform" rating and a $369.00 price target on the stock. Argus set a $370.00 price objective on shares of Stryker in a research note on Thursday, July 9th. Truist Financial upped their target price on shares of Stryker from $330.00 to $340.00 and gave the stock a "hold" rating in a research note on Friday, July 31st. Finally, Evercore set a $350.00 price target on shares of Stryker in a research report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, Stryker has an average rating of "Moderate Buy" and an average price target of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.